Toku's AI-Powered Retina Scan Navigates FDA's Breakthrough
- Toku's CLAiR platform, using AI-powered retina scans, calculates heart disease risk in 20 seconds.
- Toku secures Series A funding, backed by National Vision and Topcon Healthcare, aiming for market entry in 2025.
- Originally from Auckland, Toku relocates to San Diego, emphasizing a global vision for innovative ocular imaging.
Toku, founded by Ehsan Vaghefi, addresses cardiovascular risks through its CLAiR platform, inspired by Vaghefi's mission to make health screening accessible. The AI-powered retina scan calculates heart disease risk and related conditions in 20 seconds, with a breakthrough device designation from the FDA.
Toku aims to revolutionize routine eye exams by integrating CLAiR with existing retinal imaging cameras.
Pioneering technology garners $8 million Series A funding
Securing an $8 million Series A funding round, Toku stands at the forefront of cardiovascular health innovation. Strategic backers, including National Vision and Topcon Healthcare, position Toku for pivotal trials in mid-2024 and potential market entry by the end of 2025.
Newsletter
The corridor, every morning.
Funding rounds and cross-border capital moves, one email, five minutes.
The breakthrough designation expedites FDA accreditation, paving the way for an affordable, non-invasive approach to cardiovascular risk detection.
Global impact: Toku's journey from Auckland to San Diego
Originating in Auckland, Toku relocated its headquarters to San Diego, emphasizing its global vision for accessible health screening. The startup's expansion aligns with its commitment to bringing innovative ocular imaging to the masses, targeting retail optometry, primary care offices, and pharmacies as key deployment locations for CLAiR.
Edited by Shruti Thapa